Cover Image
Market Research Report

Diabetic Nephropathy Market and Forecast Analysis to 2026

Published by Datamonitor Healthcare Product code 618918
Published Content info 236 Pages
Delivery time: 1-2 business days
Price
Back to Top
Diabetic Nephropathy Market and Forecast Analysis to 2026
Published: February 7, 2019 Content info: 236 Pages
Description

OVERVIEW

Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether. The disease is a clinical syndrome characterized by albuminuria, decline in glomerular filtration rate, and elevated arterial blood pressure. Up to 50% of diabetics with a disease duration of over 20 years have diabetic nephropathy.

MARKET SNAPSHOT

  • An ADA/EASD consensus report will help spur use of SGLT-2 inhibitors in DN patients.
  • Survey of 216 physicians in the US, Japan, and five major EU markets sheds light on prescribing patterns.
  • In parallel with diabetes, an increase in the prevalence burden of diabetic nephropathy cases is expected during 2017-37.
  • In-depth analysis of drug classes used for the treatment of diabetic nephropathy in the US, Japan, and five major EU markets.
  • Drugs with a cardiovascular benefit will have an advantage in DN.
Table of Contents
Product Code: DMKC13716

TABLE OF CONTENTS

FORECAST: DIABETIC NEPHROPATHY (Published on 07 February 2019)

  • OVERVIEW
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS AND PIPELINE ASSESSMENT
  • FORECAST
  • MARKET DEFINITION AND METHODOLOGY
  • BIBLIOGRAPHY
  • PRIMARY RESEARCH METHODOLOGY
  • PRODUCT PROFILE (LATE STAGE): FARXIGA
  • PRODUCT PROFILE (LATE STAGE): INVOKANA
  • PRODUCT PROFILE (LATE STAGE): JARDIANCE
  • PRODUCT PROFILE (LATE STAGE): FINERENONE

TREATMENT: DIABETIC NEPHROPATHY (Published on 05 February 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • GUIDELINE RECOMMENDATIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: DIABETIC NEPHROPATHY (Published on 30 October 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: DIABETIC NEPHROPATHY (Published on 07 February 2019)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • ACE INHIBITORS
  • ANGIOTENSIN II RECEPTOR BLOCKERS

PIPELINE: DIABETIC NEPHROPATHY (Published on 07 February 2019)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • TARGET PRODUCT PROFILE
  • CLINICAL TRIAL DESIGN
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): FARXIGA
  • PRODUCT PROFILE (LATE STAGE): INVOKANA
  • PRODUCT PROFILE (LATE STAGE): JARDIANCE
  • PRODUCT PROFILE (LATE STAGE): FINERENONE

LIST OF FIGURES

  • Figure 1: Diabetic nephropathy - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for diabetic nephropathy
  • Figure 3: Presence of self-reported cardiovascular conditions among diabetics in the US, according to renal stage and albuminuria
  • Figure 4: SGLT-2 inhibitor CVOT meta-analysis, change in risk of CV death versus placebo
  • Figure 5: Diabetic nephropathy novel treatment market sales across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 6: Diabetic nephropathy sales of specific drug franchises across the US, Japan, and five major EU markets, 2025 (second to last year of the forecast)
  • Figure 7: Diabetic nephropathy novel treatment market sales in the US, 2017-26
  • Figure 8: Diabetic nephropathy novel treatment market sales in the US, individual franchises, 2017-26
  • Figure 9: Diabetic nephropathy novel treatment market sales in the five major EU markets, by country, 2017-26
  • Figure 10: Methodology flow for diabetic nephropathy
  • Figure 11: Price sources and calculations, by country
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 14: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Invokana for diabetic nephropathy
  • Figure 16: Datamonitor Healthcare's drug assessment summary of Invokana for diabetic nephropathy
  • Figure 17: Invokana sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Jardiance for diabetic nephropathy
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Jardiance for diabetic nephropathy
  • Figure 20: Jardiance sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 21: Datamonitor Healthcare's drug assessment summary of finerenone for diabetic nephropathy
  • Figure 22: Datamonitor Healthcare's drug assessment summary of finerenone for diabetic nephropathy
  • Figure 23: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 24: Percentage of incident end-stage renal disease patients with diabetes as the primary cause
  • Figure 25: Patient segmentation by albuminuria and glomerular filtration rate, with US prevalence and risk of kidney outcomes
  • Figure 26: Type 2 diabetic patients receiving antihypertensives for treatment of diabetic nephropathy according to stage of renal impairment, by country
  • Figure 27: Type 2 diabetic patients receiving RAAS inhibitors for treatment of diabetic nephropathy according to stage of renal impairment, by country
  • Figure 28: Usage of ACE inhibitors, ARBs, and renin inhibitors for diabetic nephropathy, as a percentage of antihypertensives, among type 2 diabetics, by country
  • Figure 29: Antihypertensive monotherapy versus combination therapy used to treat diabetic nephropathy in type 1 and type 2 diabetics, by country
  • Figure 30: Antihypertensive monotherapy vs combination therapy used to treat diabetic nephropathy in type 2 diabetics, by renal impairment stage and country
  • Figure 31: Percentage of type 2 diabetic patients receiving antidiabetics according to stage of renal impairment, by country
  • Figure 32: Percentage of type 2 diabetic patients receiving metformin/selected fixed-dose combinations according to stage of renal impairment, by country
  • Figure 33: Percentage of type 2 diabetic patients receiving DPP-IV inhibitors (including metformin fixed-dose combinations), by stage of renal impairment and country
  • Figure 34: Ratio of prescribing of Januvia and Tradjenta in each stage of renal impairment compared to prescribing in patients without diabetic nephropathy, by country
  • Figure 35: Percentage of type 2 diabetic patients receiving SGLT-2 inhibitors (excluding fixed-dose combinations) according to stage of renal impairment, by country
  • Figure 36: Percentage of type 2 diabetic patients receiving GLP-1 agonists and fixed-ratio combinations with insulin, by stage of renal impairment and country
  • Figure 37: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, by country
  • Figure 38: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, PCPs only, by country
  • Figure 39: Percentage of type 2 diabetic patients receiving sulfonylureas according to stage of renal impairment, by country
  • Figure 40: Compliance rates of type 2 diabetics with antidiabetic medications according to renal impairment stage, by country
  • Figure 41: Trends in total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Farxiga for diabetic nephropathy
  • Figure 44: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Invokana for diabetic nephropathy
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Invokana for diabetic nephropathy
  • Figure 47: Invokana sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Jardiance for diabetic nephropathy
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Jardiance for diabetic nephropathy
  • Figure 50: Jardiance sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 51: Datamonitor Healthcare's drug assessment summary of finerenone for diabetic nephropathy
  • Figure 52: Datamonitor Healthcare's drug assessment summary of finerenone for diabetic nephropathy
  • Figure 53: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: Exchange rates used for calculating prices
  • Table 2: Primary care physicians, diabetologists, and endocrinologists surveyed for the diabetic nephropathy primary research study, 2017
  • Table 3: Farxiga drug profile
  • Table 4: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 5: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
  • Table 6: Farxiga for diabetic nephropathy - SWOT analysis
  • Table 7: Invokana drug profile
  • Table 8: Invokana Phase III trial in diabetic nephropathy
  • Table 9: Invokana for diabetic nephropathy - SWOT analysis
  • Table 10: Jardiance drug profile
  • Table 11: Jardiance Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 12: Jardiance for diabetic nephropathy - SWOT analysis
  • Table 13: Finerenone drug profile
  • Table 14: Finerenone Phase III trials in diabetic nephropathy
  • Table 15: Finerenone Phase Iib (ARTS-DN) results in diabetic nephropathy
  • Table 16: Finerenone for diabetic nephropathy - SWOT analysis
  • Table 17: Primary care physicians, diabetologists, and endocrinologists surveyed for the diabetic nephropathy primary research study, 2017
  • Table 18: Guideline recommendations for blood pressure and glycemic control - kidney organizations
  • Table 19: Guideline recommendations for blood pressure and glycemic control - diabetes organizations
  • Table 20: Risk of cardiovascular death and end-stage renal disease according to albuminuria and eGFR (% per year)
  • Table 21: Proportion of US patients with diabetic nephropathy who are treated with antihypertensives/RAAS inhibitors, by renal stage
  • Table 22: Sources used for diabetic nephropathy analysis in the US, Japan, and five major EU markets, by country
  • Table 23: Age-standardized diabetic nephropathy prevalence proportions, by country
  • Table 24: Segmentation of diabetic nephropathy into chronic kidney disease stage
  • Table 25: Sources used to segment diabetic nephropathy prevalent cases into chronic kidney disease stage, by country
  • Table 26: Total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 27: ACE inhibitors class overview
  • Table 28: ARBs class overview
  • Table 29: Major ARB trials in type 2 diabetic nephropathy patients with severe albuminuria
  • Table 30: Profiled pipeline products in development for diabetic nephropathy
  • Table 31: Cozaar drug profile
  • Table 32: Cozaar pivotal trial data in diabetic nephropathy
  • Table 33: Atrasentan drug profile
  • Table 34: Atrasentan Phase III trial in diabetic nephropathy
  • Table 35: Farxiga drug profile
  • Table 36: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 37: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
  • Table 38: Farxiga for diabetic nephropathy - SWOT analysis
  • Table 39: Invokana drug profile
  • Table 40: Invokana Phase III trial in diabetic nephropathy
  • Table 41: Invokana for diabetic nephropathy - SWOT analysis
  • Table 42: Jardiance drug profile
  • Table 43: Jardiance Phase III trial in chronic kidney disease, including diabetic nephropathy
  • Table 44: Jardiance for diabetic nephropathy - SWOT analysis
  • Table 45: Finerenone drug profile
  • Table 46: Finerenone Phase III trials in diabetic nephropathy
  • Table 47: Finerenone Phase Iib (ARTS-DN) results in diabetic nephropathy
  • Table 48: Finerenone for diabetic nephropathy - SWOT analysis
Back to Top